Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial
Piltin M, Norwood P, Ladores V, Mukhtar R, Sauder C, Golshan M, Tchou J, Rao R, Lee M, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman L, Boughey J. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Annals Of Surgical Oncology 2024, 1-9. PMID: 38980586, DOI: 10.1245/s10434-024-15708-9.Peer-Reviewed Original ResearchPathological complete responseEvent-free survivalPatients treated with neoadjuvant chemotherapyNeoadjuvant chemotherapyDistant recurrenceLocoregional recurrenceOncological outcomesClinical trialsRate of locoregional recurrenceResponse to neoadjuvant chemotherapyInternal mammary lymphadenopathyModern neoadjuvant chemotherapyHigh tumor gradeMethodsWe evaluated patientsBreast cancer stageAxillary surgeryComplete responseMedian followTumor gradePretreatment imagingLarger tumorsPrognostic indicatorI-SPY2Comparing patientsCancer stage